Brief: Revance Therapeutics Q4 EPS USD -0.62
28/02/2024 21:05
Feb 28 (Reuters) - Revance Therapeutics Q4 product revenue USD 58.498 million. * Q4 operating expenses USD 123.752 million * Q4 pretax profit USD -55.699 million * Q4 operating income USD -53.953 million * Q4 net income USD -55.699 million
Recent news on Revance Therapeutics
See all newsBrief: Crown Laboratories and Revance Therapeutics Announce Expiration of Tender Offer
Brief: Crown Laboratories And Revance Amend A&R Merger Agreement
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Kratos, Forward Air, Bank stocks
U.S. STOCKS ON THE MOVE-Henry Schein, natgas firms, Citigroup